These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23957819)

  • 1. Emerging treatments for chronic constipation.
    Gudsoorkar VS; Quigley EM
    Expert Opin Emerg Drugs; 2013 Sep; 18(3):365-73. PubMed ID: 23957819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
    Thomas RH; Luthin DR
    Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancing treatment options for chronic idiopathic constipation.
    Quigley EM; Neshatian L
    Expert Opin Pharmacother; 2016; 17(4):501-11. PubMed ID: 26630260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and future therapies for chronic constipation.
    Tack J
    Best Pract Res Clin Gastroenterol; 2011 Feb; 25(1):151-8. PubMed ID: 21382586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives.
    Tack J; van Outryve M; Beyens G; Kerstens R; Vandeplassche L
    Gut; 2009 Mar; 58(3):357-65. PubMed ID: 18987031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments.
    Müller-Lissner S
    Expert Opin Drug Metab Toxicol; 2013 Apr; 9(4):391-401. PubMed ID: 23425050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New pharmacological treatment options for chronic constipation.
    Corsetti M; Tack J
    Expert Opin Pharmacother; 2014 May; 15(7):927-41. PubMed ID: 24661106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Some practical questions on chronic stipsis treatment with prucalopride].
    Bellacosa L; Cogliandro R; Cremon C; De Giorgio R; Barbara G; Stanghellini V
    Minerva Gastroenterol Dietol; 2014 Mar; 60(1):85-99. PubMed ID: 24632771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief.
    Pennant M; Orlando R; Barton P; Bayliss S; Routh K; Meads C
    Health Technol Assess; 2011 May; 15 Suppl 1():43-50. PubMed ID: 21609652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of prucalopride in adults with chronic idiopathic constipation.
    Vijayvargiya P; Camilleri M
    Expert Rev Clin Pharmacol; 2019 Jul; 12(7):579-589. PubMed ID: 31096799
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel pharmacological therapies for management of chronic constipation.
    Gonzalez-Martinez MA; Ortiz-Olvera NX; Mendez-Navarro J
    J Clin Gastroenterol; 2014 Jan; 48(1):21-8. PubMed ID: 24172177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional constipation in childhood: current pharmacotherapy and future perspectives.
    Hoekman DR; Benninga MA
    Expert Opin Pharmacother; 2013 Jan; 14(1):41-51. PubMed ID: 23216375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation -- a comparison in a controlled environment.
    Cinca R; Chera D; Gruss HJ; Halphen M
    Aliment Pharmacol Ther; 2013 May; 37(9):876-86. PubMed ID: 23480216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lubiprostone: chloride channel activator for chronic constipation.
    Rivkin A; Chagan L
    Clin Ther; 2006 Dec; 28(12):2008-21. PubMed ID: 17296458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of linaclotide for patients with chronic constipation.
    Lembo AJ; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; Jeglinski BI; Johnston JM
    Gastroenterology; 2010 Mar; 138(3):886-95.e1. PubMed ID: 20045700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic constipation: current pharmacologic approaches and future directions.
    Tack J; Müller-Lissner S
    Clin Gastroenterol Hepatol; 2009 May; 7(5):502-8; quiz 496. PubMed ID: 19138759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of laxative use upon symptoms in patients with proven slow transit constipation.
    Dinning PG; Hunt L; Lubowski DZ; Kalantar JS; Cook IJ; Jones MP
    BMC Gastroenterol; 2011 Nov; 11():121. PubMed ID: 22073923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome.
    Chamberlain SM; Rao SS
    Expert Opin Drug Saf; 2012 Sep; 11(5):841-50. PubMed ID: 22834474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study.
    Quigley EM; Vandeplassche L; Kerstens R; Ausma J
    Aliment Pharmacol Ther; 2009 Feb; 29(3):315-28. PubMed ID: 19035970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.